Protagonist Therapeutics, Inc. Share Price
PTGXProtagonist Therapeutics, Inc. Stock Performance
Open $99.75 | Prev. Close $98.43 | Circuit Range N/A |
Day Range $97.36 - $99.75 | Year Range $41.28 - $106.81 | Volume 33,203 |
Average Traded $98.39 |
Protagonist Therapeutics, Inc. Share Price Chart
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $99.75 | $98.93 | +0.00% |
30-Apr-26 | $99.75 | $98.93 | +0.39% |
29-Apr-26 | $100.13 | $98.55 | -2.54% |
28-Apr-26 | $99.23 | $101.12 | +2.73% |
27-Apr-26 | $100.65 | $98.43 | -1.46% |
24-Apr-26 | $103.44 | $99.89 | -2.59% |
23-Apr-26 | $106.09 | $102.55 | -2.88% |